The Most Interesting Thing in A.I. Pharma's Future - with Nicholas Thompson, Diogo Rau and Dan Priest
Jun 11, 2025
In this engaging discussion, Diogo Rau, Executive Vice President at Eli Lilly, shares insights on how AI is revolutionizing drug discovery, making it quicker to find life-saving medications. Dan Priest, Chief AI Officer at PwC, explores the future of patient experiences through AI innovations. They delve into the benefits of personalized medicine, the adaptation of AI in healthcare, and the potential of collaborative AI to tackle global issues. Their foresight into the integration of advanced technologies promises an exciting transformation for the pharma industry.
AI Snips
Chapters
Transcript
Episode notes
AI Changes Human Thinking
- Early AI models suggested a drug molecule with a completely unprecedented structure at Lilly.
- Chemists initially skeptical, it opened minds to new ideas, showing AI can also train human researchers.
AI Threatens Drug IP Protection
- AI raises risks of intellectual property theft by enabling copycats to tweak drugs to bypass patents.
- This threat endangers pharmaceutical innovation by undermining the financial incentives for new medicines.
Future Medicine Personalized Dosing
- Future medicine will be highly personalized with optimized doses based on individual characteristics.
- Current standard dosing feels antiquated compared to the precision possible in the next decade.